Aouatef Bellamine PhD

Dr. Aouatef Bellamine earned her Ph.D. in life science with honors from the University of Sorbonne in France. She is a pioneer in the field of lipid metabolism where she was the first to purify and characterize enzymes involved in cholesterol synthesis in Mycobacterium tuberculosis. Her research brought her from academia (Vanderbilt University) to industry where she led a program at Bristol-Myers Squibb looking at lip dystrophy resulting from the use of protease inhibitors and anti-psychotic drugs. Later on at BMS, she joined the metabolic disease team where she contributed to the launch of several diabetic drugs.

She also led a work stream looking at the attributes of DPP-4 inhibitors and their beneficial effects on cardiovascular outcomes, as part of the SAVOR trial. Currently, at Lonza, Dr. Bellamine is a leading member of the R&D organization in the Consumer Health and Nutrition Business Unit, where she is involved in the research and clinical development of the Nutrition portfolio. She has a proven track record and has authored over 25 peers reviewed articles and book chapters in the fields of lipid metabolism, endocrinology, and Nutrition.

She also authored several patents both in the US and Europe. She has been invited as a lecturer in many scientific conferences and has been involved in several advisory boards as a spokesperson. Dr. Bellamine is a member of the American Association for the Advancement of Science, the American Society of Nutrition, the Council for Responsible Nutrition as a senior member, the American Diabetes Association and the Society of Toxicology.